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Abstract
Homozygosity for the Egfrtm1Mag null allele in mice leads to genetic background dependent placental
abnormalities and embryonic lethality. Molecular mechanisms or genetic modifiers that differentiate
strains with surviving versus non-surviving Egfr nullizygous embryos have yet to be identified.
Egfr transcripts in wildtype placenta was quantified by ribonuclease protection assay (RPA) and the
lowest level of Egfr mRNA expression was found to coincide with Egfrtm1Mag homozygous lethality.
Immunohistochemical analysis of ERBB family receptors, ERBB2, ERBB3, and ERBB4, showed
similar expression between Egfr wildtype and null placentas indicating that Egfr null trophoblast do
not up-regulate these receptors to compensate for EGFR deficiency. Significantly fewer numbers of
bromodeoxyuridine (BrdU) positive trophoblast were observed in Egfr nullizygous placentas and
Cdc25a and Myc, genes associated with proliferation, were significantly down-regulated in null
placentas. However, strains with both mild and severe placental phenotypes exhibit reduced
proliferation suggesting that this defect alone does not account for strain-specific embryonic lethality.
Consistent with this hypothesis, intercrosses generating mice null for cell cycle checkpoint genes
(Trp53, Rb1, Cdkn1a, Cdkn1b or Cdkn2c) in combination with Egfr deficiency did not increase
survival of Egfr nullizygous embryos. Since complete development of the spongiotrophoblast
compartment is not required for survival of Egfr nullizygous embryos, reduction of this layer that is
commonly observed in Egfr nullizygous placentas likely accounts for the decrease in proliferation.
1. Introduction
EGFR is the prototypical member of a family of related receptor tyrosine kinases (RTKs) that
includes ERBB2, ERBB3, and ERBB4. The Egfr gives rise to multiple alternatively spliced
and polyadenylated transcripts [1]. Phenotypic analysis of homozygous Egfr null mutants in
mice exhibit peri-implantation to post-natal lethality, depending on the genetic background of
the mouse [2,3]. Egfr homozygous null embryos on a 129/Sv background die around 11.5 days
post-coitus (dpc) due to abnormal placental development, with a reduced spongiotrophoblast
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(ST) layer and severe disorganization of the labyrinth trophoblast (LT) layer [4]. On an outbred
CD-1 stock the ST layer is similarly reduced, but there is rescue of the disorganized LT layer
allowing Egfr null embryos to survive to birth. A more comprehensive characterization of
Egfr null embryonic lethality on many genetic backgrounds revealed that the timing of lethality
varies widely between strains [5]. Several Swiss-derived strains, on either a congenic FVB/NJ
or ICR/HaROS.129F1 backgrounds exhibit lethality prior to 10.5 dpc. Similar to the 129/Sv
strain LT defects are observed beginning at 11.5 dpc in many strains which do not support
embryonic survival, including congenic BALB/cJ and BTBR-T+ tf/J. Some backgrounds, such
as ALR.129F1 and to a lesser extent FVB.129F1 and BALB.129F1, support robust survival
of Egfr null embryos past midgestation although null placentas are smaller than those from
wildtype embryos. The existence of placental phenotypes that are strain specific suggests the
effects of EGFR deficiency on normal growth and differentiation of placenta are mediated by
background-specific modifiers.
Two separate mapping crosses have failed to yield significant quantitative trait loci associated
with survival of Egfr nullizygous embryos suggesting the existence of many modifiers with
complex relationships [5]. In addition, the molecular mechanism contributing to the Egfr null
placental phenotype has yet to be elucidated. Placental defects have been reported in animals
deficient for a number of signaling molecules downstream of EGFR. Mice deficient for the
adaptor proteins GRB2 and GAB1, Ras-specific guanine nucleotide exchange factor, SOS1
and its target KRAS, components of MAPK cascades including RAF1, MAPK2K1, ERK2 and
MAPK14 (p38), and downstream transcription factors JUNB, ETS2, and FOS all exhibit LT
defects and embryonic lethality at midgestation [6–16]. Together these data are consistent with
MAPK signaling being required for normal placental development and suggests that Egfr null
strains surviving past midgestation probably use alternate pathways to activate MAPK
signaling. Consistent with the importance of EGFR signaling for normal placental
development, EGFR is expressed in human placenta and altered expression has been associated
with intrauterine growth restriction (IUGR), preeclampsia, and placenta accreta [17–22].
In this study, we investigated potential mechanisms responsible for differential survival in the
absence of EGFR signaling, incluidng whether there is a compensatory upregulation of other
ERBB receptors. We also measured proliferation and apoptosis in EGFR-deficient placentas.
Lastly, mice double mutant for Egfr and either Trp53, Rb1, Cdkn1a, Cdkn1b or Cdkn2c were
generated.
2. Materials and methods
2.1. Mice and genetic crosses
A null allele for Egfr (Egfrtm1Mag) on outbred CD-1 stock or inbred 129/Sv, ALR/LtJ, FVB/
NJ, C57BL/6J, and BALB/cJ strains have been previously described [5]. 129S1/SvImJ and
129S6/SvEvTAC strains were used interchangably due to their highly similarity [23]. Males
heterozygous for the Egfrtm1Mag mutation, on either an ALR/LtJ, FVB/NJ, C57BL/6J, or
BALB/cJ genetic background, were mated to 129/Sv-Egfrtm1Mag females to generate F1-
Egfrtm1Mag homozygous embryos and Egfrtm1Mag heterozygous adults. The ALR.129F1
heterozygous adults were backcrossed to 129/Sv-Egfrtm1Mag/+ to obtain N2 backcross
embryos. Embryos and mice were genotyped by PCR for presence of the Egfrtm1Mag allele as
previously described [5].
Noon on the day that copulation plugs were observed was designated as 0.5 days post-coitus
(dpc). Pregnant females were euthanized by CO2 asphyxiation and embryos and placentas
dissected from the uterine horns on the morning of 9.5 through 18.5 dpc into phosphate buffered
saline (PBS). The placenta and extra-embryonic tissues were separated from the embryo by
mechanical dissection and either whole embryos before 10.5 dpc or tail biopsies after 10.5 dpc
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were collected for DNA extraction to determine the genotype of each individual embryo.
Placentas were either flash frozen or preserved in RNAlater (Ambion) for extraction of RNA
or fixed in 10% NBF (neutral buffered formalin) for histological analysis.
129/Sv-Egfrtm1Mag heterozygotes were intercrossed with mice heterozygous for Trp53tm1Tyj,
Rb1tm1Tyj, Cdkn1atm1Tyj, or Cdkn1btm1Mlf null alleles maintained on a similar 129/Sv
background. Egfrtm1Mag heterozygous mice from a BALB/cJ background were intercrossed
with mice heterozygous for Trp53tm1Tyj, Rb1tm1Tyj, or Cdkn2ctm1Yxi null alleles, also on a
BALB/cJ background. Double heterozygous mice were intercrossed and embryos with
placentas were collected and genotyped at 13.5 dpc (see Table 2). To increase numbers of
double homozygous embryos, some Trp53tm1Tyj and Cdkn1atm1Tyj crosses were set up by
intercrossing animals homozygous for Trp53tm1Tyj or Cdkn1atm1Tyj, and heterozygous for
Egfrtm1Mag. Trp53tm1Tyj, Rb1tm1Tyj, Cdkn1atm1Tyj, Cdkn1btm1Mlf and Cdkn2ctm1Yxi null alleles
were amplified by PCR and detected as previously described [24–27].
Mice were fed Purina Mills Lab Diet 5058 or 5010 and water ad libitum under specific pathogen
free conditions in an American Association for the Accreditation of Lab Animal Care approved
facility. All experiments were approved by an Institutional Animal Care and Use Committee.
2.2. Ribonuclease protection assay
Wildtype samples were collected daily from 9.5 to 16.5 dpc from CD-1 females mated to CD-1
males. Embryos were dissected from extraembryonic tissue in PBS and total RNA was isolated
from the embryo or placenta by homogenizing tissue in 1–2 mls of Tri-reagent (Molecular
Research Center). A Pvu II-Sst I restriction fragment generated from the region spanning exons
15–18 of the Egfr was subcloned into pBSK+ for use as a probe. The plasmid was linearized
with Xho I and a 440 bp antisense probe was generated and radiolabeled with T3 polymerase
and dUTP-P32 using the MAXIscript in vitro transcription kit (Ambion). The riboprobe was
quantified by scintillation counting and 10 μg of total RNA from each embryonic or placental
time point was incubated with 6 × 105 CPM (250–300 ng) labeled riboprobe. Ribonuclease
protection assays (RPAs) were carried out in triplicate using the RPA Kit II (Ambion), and
analyzed using a phosphoimager system (Molecular Dynamics). The radioactivity of each
fragment was quantified, normalized to a glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) probe, and expressed as normalized counts. Each experiment included a 20 μg sample
of total liver RNA to ensure the probe was in excess of RNA. The mouse Gapdh probe was a
280-bp Hin dIII-Pst I fragment linearized with Bam HI and antisense probe was generated
using SP6 polymerase as described above. Error is expressed as the standard error of the mean
for three independent RPAs for the embryonic and placental timepoints.
2.3. Immunohistochemistry and Western blots
FVB.129F1 and BALB.129F1 placentas at 18.5 dpc were collected and fixed in 10% neutral
buffered formalin (NBF) at 4°C overnight. Samples were then floated in 30% sucrose,
embedded in Tissue Tek (Fisher), and cryosectioned. Slides were post fixed in 10% NBF for
10 minutes, endogenous peroxidases quenched using 3% hydrogen peroxide in MeOH, and
subjected to heat-induced epitope retrieval in 10mM citrate buffer pH 6.0. Non-specific sites
were blocked using blocking solution (0.1 mM Tris pH 8.0, 0.1% Tween-20, 1% BSA)
incubated with sheep-anti-mouse-EGFR (1:100; Maine Biotech) or rabbit-anti-human-ERBB2
(sc284, 1:100), rabbit-anti-human-ERBB3 (sc285, 1:100), or rabbit-anti-human-ERBB4
(sc283, 1:100; Santa Cruz). Samples exposed to anti-EGFR were incubated in species-specific
anti-sheep secondary antibody conjugated to HRP at 1:100, while the other anti-ERBB samples
were incubated in goat anti-rabbit-HRP secondary antibody (Jackson Immunologics). Antigen
was colormetrically detected by reaction with 3-3′-diaminobenzidine (DAB) and
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counterstained with hematoxalin. Slides were photographed at 200X and the levels of
immunoreactivity were determined qualitatively.
For western analysis placentas were collected at 10.5 dpc from C57B6.129F1, 13.5 dpc from
ALR.129F1, and 18.5 dpc from FVB.129F1 crosses. Tissues were mechanically homogenized
on ice in protein lysis buffer (40mM HEPES pH 7.4, 10mM EDTA pH 8.0, 4mM EGTA pH7.5,
2% Triton X-100, 20 ng/mL aprotinin, 20 ng/mL leupeptin, 1mM sodium vanadate, 1mM
PMSF) based on 10% weight/volume. Proteins were separated using 6% stacking and 10%
resolving SDS-polyacrylamide gel electrophoresis in 1X Laemelli running buffer then
transferred to nitrocellulose membrane. Membranes were washed in TBST (10mM Tris pH7.5,
150mM NaCl, 0.1% Tween 20), blocked with 5% powdered milk in TBST, and incubated with
the following primary antibodies EGFR (1:500), ERBB3 (1:500), or mouse-anti-rat-beta
tubulin (Sigma T5201, 1:500), washed and incubated with secondary antibody to either rabbit
anti-sheep, goat anti-rabbit or rabbit-anti-mouse conjugated to HRP (Jackson Immuno) and
antigen detected using ECL detection (Amersham).
2.4. Proliferation assays
Placentas, from N2 embryos generated by backcrossing ALR.129F1-Egfrtm1Mag heterozygous
mice to 129/Sv-Egfrtm1Mag heterozygous mice, were collected two hours after maternal
intraperitoneal injection with 10 μl per gram of body weight of 25 mg/ml bromodeoxyuridine
(BrdU) in PBS. Timed pregnancies were collected at 10.5, 13.5 and 18.5 dpc, the placenta
washed in PBS, bisected, and fixed in 10% neutral buffered formalin at 4°C overnight. Tissue
was then washed in PBS and 0.9% saline, dehydrated in ethanols and xylenes then embedded
in paraffin before cutting seven-micron sections. A BrdU staining kit (Zymed) was used to
determine proliferation rates in Egfrtm1Mag homozygous null and wildtype placentas per
manufacturer’s protocol. Colorometric reaction was detected using DAB-tetrahydrochloride
horseradish peroxidase substrate, counterstained with hematoxylin, dehydrated in a series of
ethanols, and mounted using Permount (Fisher Scientific). Samples were photographed at a
magnification of 400X. BrdU positive nuclei were counted in one field of view for 5–10
independent placenta from 3–4 BrdU injected pregnant females per time point. Percentages
are expressed as the number of BrdU positive nuclei over total number of nuclei in a field of
view.
2.5. Real-time PCR
Total RNA was prepared from 129/Sv and BALB/cJ 10.5 dpc placentas using Trizol reagent
and purified using an RNAeasy mini kit according to the manufacturer’s protocol (Qiagen).
One microgram of each RNA sample was reverse transcribed with the High Capacity cDNA
Archive Kit (Applied Biosystems) and equivalent amounts of cDNA were used in a real-time
PCR reaction to measure transcript levels of Cdkn1a, Cdkn1b, Myc and Cdc25a. Levels were
normalized relative to expression of Gusb in each sample and fold change in gene expression
was calculated using the 2(−ΔΔCt) method [28]. Primer and probe sets were Assays-On-Demand
(Applied Biosysems) and used according to the manufacturer’s protocol with a Mx3000P real-
time PCR machine (Stratagene).
2.6. Statistical analysis
For BrdU experiments samples were collected from 2–5 independently injected females, with
2–10 placentas collected per gestational time. Error bars are expressed as the standard error of
the mean (SEM). Significance was determined by the Mann-Whitney test with p < 0.05 being
significant. For real-time PCR data p-values were determined by student’s T-test with p < 0.05
being significant.
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3.1. Egfr transcripts are dynamically expressed in the developing mouse placenta
Three major transcripts of Egfr have been detected in rodent tissue; 10 and 6.5-Kb transcripts
that encode the full-length 170 kD receptor and a 2.8-Kb transcript that encodes a secreted 95
kD protein corresponding to the extracellular ligand-binding domain of EGFR [29–31]. A
quantitative RPA distinguishing the full-length and truncated receptor transcripts revealed a
dynamic expression pattern during gestation. Full-length Egfr transcripts are expressed at very
low levels in the embryo from 8.5 to 10.5 dpc with expression increasing steadily from 11.5
dpc to 14.5 dpc and then decreasing after 14.5 dpc (Fig. 1A). No truncated Egfr transcripts are
detectable during embryogenesis.
In contrast to the embryonic expression pattern, both Egfr transcripts are detectable at all stages
of placental development. Expression of the full-length transcripts decrease from 9.5 to 11.5
dpc and then increase from 12.5 to 16.5 dpc, where the highest levels of expression are observed
(Fig. 1B). Interestingly, the lowest level of expression occurs around 11.5 dpc, coincident with
abnormal development of the Egfr nullizygous placenta and embryonic lethality on many
genetic backgrounds [2,3,5]. The highest level of truncated receptor transcript is observed at
9.5 dpc. When compared to levels of full-length transcript at the same time points, truncated
transcripts in the placenta decrease from 81% at 9.5 dpc to 17% at 13.5 dpc of the total Egfr
transcripts.
3.2. ERBB receptor expression is unaltered in EGFR deficient placenta
Since individual members of the ERBB family can activate similar signaling pathways, it is
possible that other ERBB family members compensate for the loss of EGFR during placental
development in strains with a less severe phenotype. To address this possibility, localization
of EGFR, ERBB2, ERBB3, and ERBB4 in 18.5 dpc wildtype and Egfrtm1Mag null placenta
was determined by immunohistochemistry.
EGFR was detected primarily in the decidua, trophoblast giant and ST cells, with low levels
detected in the LT layer (Fig. 2A). The EGFR was not detected in the Egfr null placenta at 18.5
dpc (Fig. 2B). The only ERBB family member not detected in the wildtype or Egfr null placenta
was ERBB2 (Fig. 2C and D), suggesting that in the 18.5 dpc mouse placenta this receptor is
expressed at undetectable levels or is not involved in normal placental formation. Up-regulation
of ERBB2 was not detected in response to a lack of EGFR signaling. Both ERBB3 and ERBB4
were detected in the maternal decidua and in the trophoblast giant cells of wildtype and Egfr
null placentas (Fig. 2E – H). Since dysregulation of ERBB2, ERBB3 or ERBB4 was not
detected in the Egfr null placenta, it is unlikely that these ERBB receptors contribute to
compensatory mechanisms supporting embryonic survival in the absence of EGFR.
Levels of the ERBB3 and EGFR were confirmed by western blot at 18.5 dpc, as well as at 10.5
and 13.5 dpc. No EGFR immunoreactivity was detected in homozygous Egfr null placenta,
while a normal 170 kD EGFR protein was detected in corresponding wildtype samples (Fig.
3). Higher levels of ERBB3 were detected at 18.5 dpc compared to 10.5 and 13.5 dpc in
wildtype placentas, with no significant differences noted between wildtype and Egfr null
samples. Weak bands observed in 10.5 and 13.5 dpc samples likely reflect contribution from
the deciduas, since EGFR, ERBB3 and ERBB4 are all highly expressed in the decidua.
3.3. Reduced trophoblast proliferation in EGFR deficient placentas
Differences in cellular proliferation in wildtype and Egfr null placenta were assessed by
incorporation of the thymidine analog BrdU into cells that are in the S-phase of the cell cycle.
Based on immunohistochemical analysis, the number of BrdU-positive nuclei appeared
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reduced in 10.5 dpc Egfr null placentas from 129/Sv, a strain exhibiting abnormal LT and ST
development and embryonic lethality by 11.5 dpc (Table 1). At 10.5 dpc a 60% decrease in
proliferation in the Egfr null placenta was detected compared to wildtype placenta, suggesting
that there is a significant reduction in proliferating trophoblast cells without EGFR. To
determine whether the reduction in proliferation contributes to mid-gestation lethality of
Egfr null embryos, BrdU incorporation was determined at 10.5 dpc in the ALR;129 mixed
genetic background, which has a functional LT but reduced ST layer and supports embryo
survival through late gestation. Similar to that observed in the 129/Sv background, EGFR
deficiency on the ALR;129 background resulted in a 56% reduction in BrdU positive cells.
These data suggest that proliferation does not contribute to differential survival of Egfr null
embryos.
Interestingly at 13.5 dpc of gestation, there was no longer a statistically significant difference
in BrdU incorporation between the ALR;129 wildtype and Egfr null placentas (Table 1). We
also did not observe differences in proliferation rates in specific trophoblast layers when the
amount of BrdU incorporation was analyzed specifically in the ST or LT layers at 13.5 dpc
(data not shown). By 18.5 dpc few cells are actively replicating (Table 1). Additionally there
was no significant difference in the number of trophoblast cells undergoing apoptosis when
comparing ALR;129 wildtype and Egfr null placentas at 10.5, 13.5 or 18.5 dpc using a TUNEL
assay (Table 1). We observed few TUNEL-positive trophoblasts across gestation, consistent
with previous reports haracterizing apoptosis in mouse placental tissue [7,32].
To confirm the BrdU data, markers of proliferation and cell cycle arrest were measured by
real-time PCR in 10.5 dpc Egfr wildtype and null placentas. Expression of Cdc25a and Myc,
two genes known to be transcriptionally up-regulated in proliferating cells [33,34], were
significantly higher in wildtype (n = 11) versus Egfr null (n = 12) placentas (Fig. 4). Myc
expression in Egfr null placentas was 74% of wildtype levels (p = 0.01), while Cdc25a
expression was 61% of wildtype levels (p < 0.02) (Fig. 4). Cdkn1a and Cdkn1b are known to
be transcriptionally up-regulated in cells arresting in the cell cycle at G1-S [33]. We found no
significant changes in Cdkn1a expression, but Cdkn1b transcripts were significantly higher
(117% compared to wildtype) in Egfr null placentas (p < 0.05) (Figure 4). These data are
consistent with a greater number of Egfr nullizygous trophoblast cells undergoing cell cycle
arrest.
3.4. Placental defects are not rescued by genetic reduction of cell cycle checkpoint
regulators
Although genetic backgrounds showing disparite survival of Egfr null embryos have equivalent
reductions in trophoblast proliferation at 10.5 dpc, it is possible that the ALR;129 background
overcomes the 10.5 dpc proliferation defect and continues to develop a functioning placenta
while the 129/Sv strain does not. To investigate this, we intercrossed Egfrtm1Mag heterozygous
mice with mice carrying null alleles of various cell cycle checkpoint genes that regulate the
G1 to S transition [33,35], including three cyclin dependent kinase inhibitiors (CKIs),
Cdkn1a (p21Cip1), Cdkn1b (p27Kip1), and Cdkn2c (p18INK4c), as well as two tumor suppressors,
Trp53 (p53), and Rb1. Trp53 and Cdkn1a also regulate the G2 to M checkpoint [36]. Genetic
ablation of these cell cycle checkpoint molecules would be expected to increase cellular
proliferation and, if this contributed to the mid-gestation lethality observed on the 129/Sv
background, increase survival of Egfr null embryos.
The 129/Sv background was used for Trp53tm1Ty, Rb1tm1Tyj, Cdkn1atm1Tyj, and
Cdkn1btm1Mlf null allele crosses while the BALB/cJ background, which has a phenotype similar
to 129/Sv, was used for Trp53tm1Ty, Cdkn2ctm1Yxi and Rb1tm1Tyj null allele crosses. Surviving
Egfrtm1Mag homozygous embryos were not detected at 13.5 dpc irrespective of Trp53tm1Tyj (n
= 120), Rb1tm1Tyj (n = 108), or Cdkn1btm1Mlf (n = 102) genotype (Table 2). At 13.5 dpc a low
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number of viable embryos from the Cdkn2ctm1Yxi cross were found to be homozygous for
Egfrtm1Mag (2 out of 119). However, one of these two embryos was wildtype for Cdkn2c.
Similarly 12 out of 257 total embryos from the Cdkn1atm1Tyj cross were found to be
Egfrtm1Mag homozygous and viable at 13.5 dpc. Data from Cdkn1atm1Tyj, Egfrtm1Mag
heterozygous intercrosses revealed that 3 of the 5 surviving Egfr nullizygous embryos carried
wildtype Cdkn1a alleles. Because genotypes of Cdkn1atm1Tyj or Cdkn2ctm1Yxi did not correlate
with embryonic survival it is likely that Cdkn1atm1Tyj and Cdkn2ctm1Yxi congenic lines were
not pure 129/Sv or BALB/cJ and were probably segregating unknown genetic background
modifiers of the Egfrtm1Mag phenotype. In composite, these data indicate that removing
negative regulators of the cell cycle is not sufficient to support survival of Egfr null embryos.
4. Discussion
EGFR transcripts and protein are abundantly detected in human placenta and aberrant
expression of the receptor has been associated with IUGR, preeclampsia, and placenta accreta
[17–22]. Interestingly, alternative transcripts from the Egfr locus that encode a secreted 60 kD
protein corresponding to the extracellular ligand binding domain of EGFR have been reported
in both human and mouse placenta [1,21,37,38]. Using RPA we demonstrated dynamic
expression of Egfr transcripts during mouse embryo and placental development. Truncated
Egfr transcripts were not detected in the developing embryo, but low levels detected throughout
placental development raise the possibility that secreted, ligand-binding EGFR may negatively
regulate EGFR signaling in extra-embryonic tissue. In addition, we observed up-regulation of
full-length Egfr transcripts after 11.5 dpc suggesting that EGFR is actively being turned-over
around the time that the placental LT develops and begins to function. Since RPA provides no
information on the localization of Egfr transcripts the dynamic expression patterns observed
may reflect differences in the composition of the placenta related to gestational age rather than
changes in Egfr expression; EGFR can be detected in all layers of the developing mouse
placenta by immunohistochemistry.
One potential explanation for strain-specificity of the Egfr nullizygous placental phenotype is
that surviving strains may developmentally compensate for a lack of Egfr signaling by up-
regulating expression of other ERBB family members, similar to that demonstrated in the
Ptgs2 null mouse uterus where up-regulation of Ptgs1 allows partial rescue of fertility defects
in CD-1 females [39]. We compared expression of ERBB2, ERBB3, and ERBB4 in wildtype
and Egfr null placentas from two hybrid strains that survive until late gestation. ERBB2 was
not detected, and although ERBB3 and ERBB4 were detected in the decidua and trophoblast
giant cells at late gestation, there was no difference in expression or localization between
Egfr wildtype and null placentas. In fact, EGFR-deficient strains that survive past mid-gestation
probably utilize a mechanism other than ERBB compensation since ERBB2, ERBB3, and
ERBB4 are not expressed at detectable levels in the ST or LT, where defects in the Egfr
nullizygous placenta are primarily observed.
EGFR plays an important role in regulating cellular proliferation and cell survival [40]. EGFR
signaling has been shown to promote cell cycle progression through the G1-S, as well as G2-
M checkpoints, and it is possible that the strain-specific placental phenotype observed in
Egfr null mice could result from surviving strains using alternate pathways to enhance cell
cycle progression in trophoblasts [41]. We found that Egfr null placentas on 129/Sv and ALR.
129 genetic backgrounds have fewer BrdU-positive trophoblasts than wildtype at 10.5 dpc.
However, proliferation defects in the Egfr nullizygous placentas do not correlate with
embryonic lethality since Egfr null embryos on ALR.129 survive to late gestation despite
having equivalently reduced trophoblast proliferation compared to embryos on a 129/Sv
background at 10.5 dpc,. This result does not exclude the possibility that the ALR;129, but not
the 129/Sv genetic background, harbors modifiers allowing the strain to overcome proliferation
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defects at 10.5 dpc and develop a functioning placenta. We tested this hypothesis by genetically
reducing negative cell cycle regulators downstream of EGFR, thus potentially permitting cell
cycle progression in the absence of EGFR on backgrounds that do not support survival of
Egfr null embryos past mid-gestation. Hyper-proliferation of LT has been observed in mouse
RB1-deficient placentas and in placentas deficient for both CDKN1B and CDKN1C [42–44].
We surmised that eliminating these and other cell cycle checkpoint components would rescue
Egfr nullizygous placental development by increasing trophoblast proliferation. We
intercrossed Egfrtm1Mag heterozygotes with mice segregating Trp53tm1Tyj, Rb1tm1Tyj,
Cdkn1atm1Tyj, Cdkn1btm1Mlf or Cdkn2ctm1Yxi null alleles carried on 129/Sv and BALB/cJ
backgrounds. Results from the intercrosses indicated that genetic reduction of negative cell
cycle checkpoint components does not rescue the embryonic lethality of EGFR deficient
embryos.
Together our data indicates that proliferation defects observed in 10.5 dpc Egfrtm1Mag
nullizygous placentas do not contribute to the midgestation embryonic lethality since the
phenotype is observed in both surviving (ALR;129) and non-surviving (129/Sv) strains. At
10.5 dpc the ST is likely the primary lineage affected by the proliferation defect because both
ALR;129 and 129/Sv show dramatic reduction of this trophoblast compartment. Consequently,
a decrease in the ST population probably does not contribute to placental insufficiency in
Egfr nullizygous embryos. Rather, survival of embryos beyond 11.5 dpc is prevented by an
abnormal LT phenotype in strains such as 129/Sv. Additional experiments utilizing markers
for trophoblast sub-type progenitors are necessary to evaluate differences in early LT cell
populations that may distinguish surviving and non-surviving strains.
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Expression profile of Egfr during development. Graphs of normalized counts from (A)
embryonic and (B) placental RNase protection assays at gestational time points 9.5 to 16.5
dpc. Transcript levels were quantitated by phosphoimager analysis, normalized to Gapdh
expression and expressed as normalized counts on the Y-axis. Blue lines represent full-length
Egfr transcript levels and red lines represent truncated Egfr levels. Error is represented as
standard error of the mean (SEM).
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Immunohistochemistry for ERBB family members on late gestation placentas.
Immunohistochemistry was done using FVB.129 or BALB.129N2 placentas at 18.5 dpc.
Panels (A, C, E, G) are wildtype samples, while (B, D, F, H) are Egfrtm1Mag null samples. (A,
B) Protein localization for an EGFR specific antibody. In wildtype sample EGFR is localized
to both the spongiotrophoblast and labyrinthine layers. Note loss of localization of EGFR in
the Egfrtm1Mag null placenta, although there is some immunoreactivity in the maternally
derived decidual layer. Also note the loss of the spongiotrophoblast cell layer. (C, D) ERBB2
is not detected in either wildtype or null samples. (E, F) Localization of ERBB3 protein to the
TGC layer and the maternal decidua. Levels of protein appear equivalent in both the wildtype
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and Egfrtm1Mag null placenta. (G, H) Protein levels of ERBB4 appear unaltered between the
wildtype and Egfrtm1Mag null samples, with localization observed in the TGC and maternal
decidua. SP, spongiotrophoblast layer; LT, labyrinthine trophoblast layer; De, decidua; TGC,
trophoblast giant cells. Arrowheads indicate TGC. Scale bars are 50 μm.
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Western blot analysis of EGFR, ERBB3 and TUBB1 (beta-tubulin) during placental
development. Protein lysates are from Egfr wildtype or null placentas isolated at the indicated
time points. Beta tubulin represents loading control.
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Real-time PCR expression analysis of proliferation and cell cycle arrest markers. RNA from
10.5 dpc placenta are identified by open bars, Egfr wildtype and gray bars, Egfr null. Y-axis
represents the percent change in gene expression compared to the average expression in
wildtype samples adjusted to 100%. Expression of proliferation, Myc and Cdc25a, and cell
cycle arrest, Cdkn1a and Cdkn1b, markers are presented.
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